Patents Assigned to The Government of the USA, as represented by the Secretary, Department of Health & Human Services
  • Patent number: 11311509
    Abstract: The subject disclosure provides compositions for reducing serum cholesterol and/or triglyceride levels in subjects. These compositions can comprise racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, optionally in the acid form, physiologically compatible salts of racemic ?-hydroxybutyrate or D-?-hydroxybutyrate, esters of D-?-hydroxybutyrate, oligomers of D-?-hydroxybutyrate containing from 2 to 20 or more monomeric units in either linear or cyclic form, racemic 1,3 butandiol or R-1,3 butandiol alone and can be, optionally, administered in conjunction with a low fat diet to a subject.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: April 26, 2022
    Assignees: OXFORD UNIVERSITY INNOVATION LIMITED, Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Publication number: 20220105186
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: November 2, 2021
    Publication date: April 7, 2022
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human Services
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Patent number: 10821062
    Abstract: A method of protecting animal tissue particularly skin, from damage caused by radiation exposure, by contacting the tissue with a ketone ester, a method of protecting skin, reducing the deterioration of skin or maintaining or improving the properties of skin by applying topically to the skin a ketone body comprising (R)-3-hydroxybutyrate moieties is disclosed. A ketone body comprising (R)-3-hydroxybutyrate moieties, especially enantiomerically enriched R-1,3-hydroxybutyl-(R)-3-hydroxybutyrate, for such uses is also provided.
    Type: Grant
    Filed: September 16, 2013
    Date of Patent: November 3, 2020
    Assignees: TDELTAS LIMITED, GOVERNMENT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Publication number: 20200188515
    Abstract: This invention encompasses methods of preserving protein function by contacting a protein with a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese). In addition, the invention encompasses methods of treating and/or preventing a side effect of radiation exposure and methods of preventing a side effect of radiotherapy comprising administration of a pharmaceutically effective amount of a composition comprising one or more purine or pyrimidine nucleosides (such as e.g., adenosine or uridine) and an antioxidant (such as e.g., manganese) to a subject in need thereof. The compositions may comprise D. radiodurans extracts.
    Type: Application
    Filed: July 8, 2019
    Publication date: June 18, 2020
    Applicants: The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., The Government of the USA as Represented by the Secretary Department of Health and Human Services
    Inventors: Michael J. Daly, Elena K. Gaidamakova, Vera Y. Matrosova, Rodney L. Levine, Nancy B. Wehr
  • Publication number: 20160367658
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: September 6, 2016
    Publication date: December 22, 2016
    Applicants: The Government of the USA, as represented by the Secretary, Department of Health and Human Services, Mahidol University
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Publication number: 20140194509
    Abstract: A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R)-hydroxybutyl (3R)-hydroxybutyrate of formula (I) is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of neurodegeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.
    Type: Application
    Filed: December 10, 2013
    Publication date: July 10, 2014
    Applicants: Government of the USA, as Represented by the Secretary, Department of Health and Human Services, Isis Innovation Limited
    Inventors: Kieran Clarke, Richard Lewis Veech
  • Publication number: 20140141040
    Abstract: Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses.
    Type: Application
    Filed: January 28, 2014
    Publication date: May 22, 2014
    Applicants: Mahidol University, The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Richard M. Kinney, Claire Y.H. Kinney, Siritorn Butrapet, Duane J. Gubler, Natth Bhamarapravati
  • Publication number: 20130052226
    Abstract: The invention provides a codon-optimized parvovirus polynucleotide composition and methods of expressing this polynucleotide in a variety of mammalian cells, including non-erythroid progenitor cells, to produce immunogenic compositions.
    Type: Application
    Filed: February 9, 2011
    Publication date: February 28, 2013
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Ning Zhi, Neal S. Young, Sachiko Kajigaya
  • Publication number: 20130011433
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Application
    Filed: November 28, 2011
    Publication date: January 10, 2013
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph Blaney, Kathryn Hanley
  • Publication number: 20120328640
    Abstract: The instant invention provides compositions for the treatment of cancer. Specifically, the invention provides polypeptides and nucleic acid molecules comprising tumor-associated embryonic antigens, e.g., OFA-iLRP, and chemoattractant ligands, e.g., a proinflammatory chemokine such as MIP3?/CCL20 or ?-defensin mDF2?. The invention further provides cancer vaccines and methods for treating subjects having, or at risk of developing, cancer.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 27, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Bira Arya, Dan Longo, Igor Espinoza
  • Publication number: 20120282701
    Abstract: The invention is related to intracellularly induced bacterial DNA promoters and vaccines against Bacillus anthracis.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 8, 2012
    Applicant: Government of the USA, as Represented by the Secretary, Department of Health and Human Services
    Inventors: DENNIS J. KOPECKO, MANUEL OSORIO, SIBA BHATTACHARYYA, CHANDRAKANT P. GIRI, MILAN BLAKE
  • Publication number: 20120277286
    Abstract: The present invention features compositions and methods for the treatment or prevention of diseases associated with a mitochondrial defect.
    Type: Application
    Filed: May 1, 2012
    Publication date: November 1, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Richard J. Youle, Derek Narendra, Der-Fen Suen
  • Publication number: 20120201907
    Abstract: Administration of an HNO/NO? donating compound, such as Angeli's salt, increases myocardial contractility while concomitantly lowering left ventricular preload in subjects experiencing heart failure. Moreover, administration of the HNO/NO? donating compound isopropylamine (IPA)/NO (Na(CH3)2CHNHN(O)NO) surprisingly exhibited positive inotropic effects in subjects experiencing heart failure that were superior to those caused by the HNO/NO? donating compound Angeli's salt. Additionally, in contrast to the effects observed with NO donors, administration of an HNO/NO? donor in combination with a positive inotropic agent did not impair the positive inotropic effect of the positive inotropic agent. Further, HNO/NO? exerts its positive inotropic effect independent of the adrenergic system, increasing contractility even in subjects receiving beta-antagonist therapy.
    Type: Application
    Filed: April 13, 2012
    Publication date: August 9, 2012
    Applicants: The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, Johns Hopkins University, The Regents of the University of California, Government of the USA represented by the Secretary of the Department of Health and Human Services
    Inventors: David A. WINK, Martin FEELISCH, David A. KASS, Nazareno PAOLOCCI, Katrina MIRANDA, Jon FUKUTO, Tatsuo KATORI
  • Publication number: 20120114694
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 10, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • Publication number: 20120107358
    Abstract: The present invention discloses the construction of dengue virus subgenomic replicons containing large deletions in the structural region (C-preM-E) of the genome, which replicons are useful as vaccines to protect against dengue virus infection.
    Type: Application
    Filed: September 23, 2011
    Publication date: May 3, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Xiaowu Pang, Andrew I. Dayton, Mingjie Zhang
  • Publication number: 20100029547
    Abstract: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1?6)Man-beta (1?4) GlcNAc-beta(1?4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also relates to an isolated polypeptide comprising one or more copies of the sequence GPLWSNXEAQXXGPX (SEQ ID NO: 1) and/or one or more copies of the sequence FTGQWXTXVEXXMSV (SEQ ID NO: 2), wherein the polypeptide binds specifically to the above-mentioned oligosaccharide. Conjugates comprising such polypeptides and an effector molecule are also disclosed, as are methods of using such polypeptides or conjugates, e.g., for inhibiting infection by a virus, such as HIV, or for removing a virus, such as HIV, from a sample, such as a bodily fluid or an inanimate object.
    Type: Application
    Filed: March 9, 2005
    Publication date: February 4, 2010
    Applicant: The Government of the USA as represented by the Secretary, Department of Health and Human Services
    Inventor: Carole A. Bewley
  • Publication number: 20080226559
    Abstract: Disclosed are benztropine analogs having the formula (I) in which Ar is a C6-C20 monocyclic aryl group or a C10-C20>bicyclic aryl group or a heteroaryl, heterocyclic, or arylheterocyclic group having 2 to 12 carbon atoms and one or more heteroatoms selected from the group consisting of N, O, S, P, and any combination thereof; m=1 to 5; n=1 to 3; and R1 to R4 are as described in the specification; or a pharmaceutically acceptable salt or solvate thereof; pharmaceutical compositions and use thereof, e.g., in treating mental disorders.
    Type: Application
    Filed: August 24, 2006
    Publication date: September 18, 2008
    Applicant: GOVERNMENT OF THE USA,REPRESENTED BY THE SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Amy Hauck Newman, Mu-Fa Zou, Jonathan L. Katz
  • Publication number: 20070087356
    Abstract: The invention provides a microarray and methods for producing a protein microarray. The array comprises multiple nucleic acid molecules immobilized on a substrate, each comprising (i) a protein-binding domain and (ii) a nucleic acid sequence encoding a fusion protein comprising a polypeptide of interest and a DNA-binding protein that binds the protein-binding domain, and one or more fusion proteins produced from the multiple nucleic acid molecules. Each fusion protein is immobilized on the substrate via binding to a nucleic acid sequence comprising the protein-binding domain present on the nucleic acid molecule from which the fusion protein is produced or on the substrate. The invention also provides a method of analyzing protein interactions with, for example, other proteins, lipids and drugs.
    Type: Application
    Filed: October 19, 2005
    Publication date: April 19, 2007
    Applicant: Government of the USA, represented by the Secretary, Department of Health & Human Services
    Inventors: Deb Chatterjee, Kalavathy Sitaraman, James Hartley, Cassio Baptista, David Munroe
  • Publication number: 20070048860
    Abstract: The present invention relates to novel modified CEA agonist (or antagonist) peptides, polypeptides and proteins containing a modified epitope therein, nucleic acids coding therefor, vectors comprising said nucleic acids, mixtures and compositions of the aforementioned agents, and their advantageous use in generating CEA-specific immune responses and/or in the treatment of cancers and the present invention further relates to the foregoing combined with one or more costimulatory molecules.
    Type: Application
    Filed: December 30, 2005
    Publication date: March 1, 2007
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Jeffrey Schlom, James Hodge, Sam Zaremba, Maria Salazar
  • Publication number: 20060275865
    Abstract: The present invention relates, in general, to autotaxin. In particular, the present invention relates to a DNA segment encoding autotaxin; recombinant DNA molecules containing the DNA segment; cells containing the recombinant DNA molecule; a method of producing autotaxin; antibodies to autotaxin; and identification of functional domains in autotaxin.
    Type: Application
    Filed: February 16, 2005
    Publication date: December 7, 2006
    Applicant: Government of the USA, as represented by the Secretary Department of Health & Human Services
    Inventors: Mary Stracke, Lance Liotta, Elliott Schiffmann, Henry Krutzch, Jun Murata